Vaxart Inc. (VXRT) News
Filter VXRT News Items
VXRT News Results
|Loading, please wait...|
VXRT News Highlights
- For VXRT, its 30 day story count is now at 6.
- Over the past 12 days, the trend for VXRT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about VXRT are NOV and STEP.
Latest VXRT News From Around the Web
Below are the latest news stories about VAXART INC that investors may wish to consider to help them evaluate VXRT as an investment opportunity.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript November 2, 2023 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.18. Operator: Greetings, and welcome to the Vaxart Business Update and Third Quarter 2023 Financial Results Conference Call. A question-and-answer session will follow management’s opening remarks. Individual investors may submit written questions to […]
Company highlights progress in norovirus and COVID-19 vaccine developments and financial performance
Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the Company’s oral pill vaccine platform now established in two human challenge studies for norovirus and influenza Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business
Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers. “Initiating this study is an important step toward Vaxart’s goal of developing a vaccine that may reduce
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage!
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on Thursday, November 2, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Clic
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023. Presentation Information: Title: Transmission blocking strategies via oral tablet vaccination and mucosal immune inductionSpeaker: Dr. Sean TuckerDate:
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference in New York on Thursday, September 28, 2023 at 2:25 p.m. ET. The webcast of the fireside chat will be available on the Company’s Investor Presentations & Events page. A replay will be available on the Company’s website following the event. Management will also participate in one-on-on
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.